Kalydeco and Diabetes - a phase IV clinical study of FDA data

Summary:

Diabetes is reported as a side effect among people who take Kalydeco (ivacaftor), especially for people who are female, 40-49 old, have been taking the drug for 6 - 12 months also take Pulmozyme, and have Cystic fibrosis.

The phase IV clinical study analyzes which people have Diabetes when taking Kalydeco. It is created by eHealthMe based on reports of 6,645 people who have side effects when taking Kalydeco from the FDA, and is updated regularly.

What is Kalydeco?

Kalydeco has active ingredients of ivacaftor. eHealthMe is studying from 6,652 Kalydeco users. Check the latest studies of Kalydeco.

What is Diabetes?

Diabetes is found to be associated with 2,010 drugs and 2,858 conditions by eHealthMe. Check the latest studies of Diabetes.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 21, 2026

6,645 people reported to have side effects when taking Kalydeco.
Among them, 17 people (0.26%) have Diabetes.

Among these 17 people:

How long have people been on Kalydeco when they have Diabetes? *

What is the gender of people who have Diabetes when taking Kalydeco? *

female: 52.94 %
male: 47.06 %

What is the age of people who have Diabetes when taking Kalydeco? *

What are other drugs people take besides Kalydeco? *

What are other side effects people have besides Diabetes? *

Drug Ineffective: 2 people, 11.76%
Fatigue (feeling of tiredness): 2 people, 11.76%
Forced Expiratory Volume Decreased (decreased lung expired air volume): 2 people, 11.76%
Impaired Healing: 2 people, 11.76%
Weight Decreased: 1 person, 5.88%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 5.88%
Burkholderia Test Positive: 1 person, 5.88%
Consciousness - Decreased: 1 person, 5.88%
Depression: 1 person, 5.88%
Distal Intestinal Obstruction Syndrome (blockage of the intestines by thickened stool and occurs in individuals with cystic fibrosis): 1 person, 5.88%

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 17 people, 100.00%
Staphylococcal Infection (an infection with staphylococcus bacteria): 1 person, 5.88%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 1 person, 5.88%
Osteopenia (a condition where bone mineral density is lower than normal): 1 person, 5.88%
Infection: 1 person, 5.88%
Burkholderia Cepacia Complex Infection (complex infection by group of bacteria burkholderia cepacia -resistant to common antibiotics): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Kalydeco and have Diabetes?

- Check whether Diabetes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kalydeco:

Kalydeco (6,652 reports)

Diabetes treatments and more:

Diabetes (466,616 reports)

Browse all side effects of Kalydeco:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diabetes:

Diabetes (2,010 drugs)

Browse all the conditions that are associated with Diabetes:

Diabetes (2,858 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ivacaftor (the active ingredients of Kalydeco) and Kalydeco (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.